To date, researchers have not developed fully functional human immune systems, but only those with a brief lifespan that do not develop efficient immune responses, allowing them to develop in vivo human immunotherapy, human disease modeling, or human vaccine development. Become unsuitable...
Nipah virus is a zoonotic disease of the paramyxovirus family, which causes death in 75 percent of people infected. The transmission rate of this deadly disease is also high. To date, there are no approved treatments or vaccines against it.The objective of the trial is to assess the safety and...
The biosimilar bevacizumab will be manufactured at its new multi-product monoclonal antibody (mAbs) drug substance facility in Bengaluru, the company said in a statement.This approval will provide significant additional capacity to meet the needs of patients across all markets in Europe. The...
CCMB, a part of the Council of Scientific and Industrial Research (CSIR), has signed a comprehensive MoU (Agnitha's Generative AI MoU) to implement small molecule and Solutions for antibody design.Initial areas of collaboration include target analysis, small molecule design and antibody and...
Although not new, VITT emerged as a new disease after the adenovirus vector-based Oxford-AstraZeneca vaccine2021."An unusually virulent blood autoantibody directed against the protein term platelet factor 4 (or PF4)" was found to be the cause of VITT.In separate research in 2023...
Researchers at the Indian Institute of Science (IISc), Bengaluru, have designed a synthetic compound (antigen) that can capture proteins in the blood and reach the lymph node, where it can promote the production of antibodies against cancer cells.According to a press release issued by...